# Universal Influenza A Vaccine in Healthy Adults

> **NCT05155319** · PHASE1 · COMPLETED · sponsor: **Emergent BioSolutions** · enrollment: 27 (actual)

## Conditions studied

- Human Influenza

## Interventions

- **BIOLOGICAL:** UFluA 20 µg each antigen/dose
- **BIOLOGICAL:** UFluA 60 µg each antigen/dose
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05155319
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2023-10-10
- **Final completion:** 2023-10-10
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155319, "Universal Influenza A Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05155319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*